Meeting
2021 ASCO Annual Meeting
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.
Authors
Carlo Gambacorti-Passerini
University of Milano-Bicocca, Monza, Italy
Carlo Gambacorti-Passerini , Tim H. Brümmendorf , Dong-Wook Kim , Yeow Tee Goh , Irina S Dyagil , Katia Pagnano , Arpad Batai , Anna G. Turkina , Eric Leip , Simon Purcell , Jocelyn M Leone , Andrea Viqueira , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT00261846 and NCT01903733
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7009)
DOI
10.1200/JCO.2021.39.15_suppl.7009
Abstract #
7009
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
First Author: Tim H. Brümmendorf
Poster
2018 ASCO Annual Meeting
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
First Author: Carlo Gambacorti-Passerini
Poster
2012 ASCO Annual Meeting
Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).
First Author: Tim H. Brummendorf
Poster
2023 ASCO Annual Meeting
ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI).
First Author: Ehab L. Atallah